It has been a mixed year for Damora Therapeutics, Inc. insiders: $253,000 bought by one person and $7,345 sold by one, so more buying than selling overall.
Biggest single buyer: Jarrett Jennifer, CEO, with roughly $253,000. Notably, at least one C-suite executive was among the buyers.
Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 101 funds reported holding DMRA at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Jarrett Jennifer | CEO | Buy | 12,500 | $20.23 | $253K | SEC |
| Jul 7, 2026 | Winslow Garrett | Executive Officer | Sell | 245 | $29.98 | $7K | SEC |
In the last 12 months Damora Therapeutics, Inc. insiders made open-market purchases worth about $253,000 and sales worth about $7,345. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in DMRA was filed on 2026-09-28.
101 investment managers reported holding DMRA in SEC Form 13F filings for Q2 2026.
No congressional trades in DMRA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).